Who
Richard Douglas
Director
Company insider
Files Form 4 as: Director, Novavax; Director, MaxCyte; Director, Aldeyra Therapeutics; Director, Intercell USA.
In numbers
- Trades disclosed
- 117
- Buys
- 18
- Sells
- 0
- Bought
- $2.3M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 16 May 2006
- Last trade
- 20 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,909 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,323 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,909 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,323 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $98K70,000 at $1.40 | filing |
| 19 Mar 2026filed 20 Mar 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $98K70,000 at $1.40 | filing |
News
No headline names them, or the companies they trade most, lately.